Characteristics

N (%)

Median

At Diagnosis

 

 

Age, years

256 (100%)

56 (range 17-76)

Gender

 

 

Male

158 (62%)

 

Female

98 (38%)

 

Extra-nodal sites

 

 

0

171 (66.7%)

 

1

64 (25%)

 

2

17 (7%)

 

3

3 (1%)

 

4

1 (0.3%)

 

LDH (U/L)

256 (100%)

234.5 (range 110-2400)

PS

 

 

0

56 (22%)

 

1

192 (75%)

 

2

8 (3%)

 

Stage

 

 

I

32 (13%)

 

II

43 (17%)

 

III

57 (22%)

 

IV

124 (48%)

 

IPI risk factors

 

 

Age, years

 

 

> 60

94 (37%)

 

≤ 60

162 (63%)

 

Extra-nodal sites

 

 

> 1

21 (8%)

 

≤ 1

235 (92%)

 

LDH (U/L)

 

 

abnormal

126 (49%)

 

normal

130 (51%)

 

PS

 

 

> 1

8 (3%)

 

≤ 1

248 (97%)

 

Stage

 

 

I/II

75 (29%)

 

III/IV

181 (71%)

 

IPI score

 

 

0

32 (13%)

 

1

79 (31%)

 

2

101 (39%)

 

3

38 (15%)

 

4

6 (2%)

 

IPI

 

 

≥ 2

145 (57%)

 

< 2

111 (43%)

 

At relapse

 

 

Age-R

 

 

> 60

98 (38%)

 

≤ 60

158 (62%)

 

Extra nodal sites-R

 

 

> 1

29 (11%)

 

≤ 1

227 (89%)

 

LDH-R

 

 

abnormal

120 (47%)

 

normal

136 (53%)

 

PS-R

 

 

> 1

30 (12%)

 

≤ 1

226 (88%)

 

Stage-R

 

 

I/II

109 (43%)

 

III/IV

147 (57%)

 

IPI-R

 

 

> 2

60 (23%)

 

≤ 2

196 (77%)

 

Pre-transplant Rituximab

 

 

No

137 (54%)

 

Yes

119 (46%)

 

Number of prior treatments before transplant

 

 

2

220 (86%)

 

3

33 (135)

 

4

3 (1%)

 

At Transplant

 

 

Age, years

256 (100%)

57 (range 17-77)

Outcome prior to transplant

 

 

CR

66 (26%)

 

PR

190 (74%)

 

Conditioning regimens

 

 

CTX/TBI

6 (2%)

 

BEAC

47 (19%)

 

BEAM

203 (79%)

 

Infused CD34

256 (100%)

3.4 (range 2.0-14.9)


Abbreviations: Age-R= age at relapse; Extra nodal sites-R = extranodal sites at relapse; LDH = lactate dehydrogenase; LDH-R = lactate dehydrogenase at relapse; PS = performance status; PS-R; performance status at relapse; Stage-R = stage at relapse; IPI = International Prognostic Index; IPI-R = International Prognostic Index at relapse; CTX= cyclophosphamide; TBI = Total body irradiation: BEAC = BCNU, etoposide, Ara-C, and cyclophosphamide; BEAM = BCNU, etoposide, Ara-C, and melphalan; CR = complete remission; PR = partial response.
Table 1: Baseline patients’ characteristics.